News Conference News EACTS 2024 Will Semaglutide Change Cardiac Surgery? It Already Has Yael L. Maxwell October 10, 2024
News Conference News ESC 2023 ESC Focused Update on HF Synthesizes New Trial Data for Practical Use L.A. McKeown September 01, 2023
News Conference News ESC 2023 New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground Caitlin E. Cox August 30, 2023
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News ACC 2023 CRP More Predictive of Future Events Than LDL in Statin-Treated Patients Caitlin E. Cox March 14, 2023
News Conference News ACC 2023 Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT Yael L. Maxwell March 07, 2023
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Conference News HFSA 2020 EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes L.A. McKeown October 09, 2020
News Conference News ESC 2019 New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL Michael O'Riordan September 05, 2019
News Conference News EAS 2018 Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics Yael L. Maxwell May 16, 2018